medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2017, Number 05-06

<< Back Next >>

Medicina & Laboratorio 2017; 23 (05-06)

Clinical utility of the measurement of the anti-müllerian hormone in women

Henao-Ochoa C, Lasprilla-Tovar JD, Alfaro-Velásquez JM, Campuzano-Maya G

Language: Spanish
References: 140
Page: 213-236
PDF size: 613.54 Kb.


ABSTRACT

Anti-mullerian hormone is a homodimeric glycoprotein belonging to the transforming growth factor beta (TGF-β) super family. Anti-mullerian hormone plays a fundamental role in the regression of mullerian ducts in male embryo. In boys, it is produced by Sertoli cells of the testes until puberty where slowly decreases to residual values for the rest of the life. In female, it is secreted by granulosa cells of small follicles in the ovary where their levels accurately reflect the ovarian follicular reserve. Therefore, anti-mullerian hormone has been considered as extremely sensitive marker of ovarian aging and a valuable tool in the diagnosis and the recognition of recurrence of granulosa cell tumor. Anti-mullerian hormone evaluation is also of clinical importance in predicting of ovarian responsiveness, ovarian function cessation, and in assisted reproduction. In addition, anti-mullerian hormone could be a diagnostic marker of polycystic ovary syndrome in cases in which ultrasonographic examination is not possible. Finally, the measurement of serum anti-mullerian hormone levels during woman’s reproductive life represents an ideal tool for the assessment of the ovarian follicular reserve. This review presents the physiological role of anti-mullerian hormone in women, as well as the main clinical benefits of its measurement and the laboratory tests available for this purpose.


REFERENCES

  1. Josso N, Rey RA, Picard JY. Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. Int J Endocrinol 2013; 2013: 674105.

  2. Edelsztein NY, Grinspon RP, Schteingart HF, Rey RA. Anti-müllerian hormone as a marker of steroid and gonadotropin action in the testis of children and adolescents with disorders of the gonadal axis. Int J Pediatr Endocrinol 2016; 2016: 20.

  3. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of Anti-müllerian hormone in women. Hum Reprod Update 2014; 20: 370-385.

  4. Grynnerup AG, Lindhard A, Sorensen S. Recent progress in the utility of Anti-müllerian hormone in female infertility. Curr Opin Obstet Gynecol 2014; 26: 162- 167.

  5. Omabe M, Ezeani M, Martin O. Clinical Utilities of Anti-müllerian Hormone. Sch J App Med Sci 2013; 1: 606-618.

  6. Achermann JC, Hughes IA. Trastornos pediátricos del desarrollo sexual. En: Melmed S, Polonsky K, Larsen PR, Kronenberg H, eds. Williams Tratado de endocrinología + ExpertConsult (ed 13a). Barcelona, España: Elsevier; 2017: 893-963.

  7. Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of mammalian gonad development. Nat Rev Endocrinol 2014; 10: 673-683.

  8. Smith P, Wilhelm D, Rodgers RJ. Development of mammalian ovary. J Endocrinol 2014; 221: R145-161.

  9. Fowler PA, Anderson RA, Saunders PT, Kinnell H, Mason JI, Evans DB, et al. Development of steroid signaling pathways during primordial follicle formation in the human fetal ovary. J Clin Endocrinol Metab 2011; 96: 1754-1762.

  10. Feng CW, Bowles J, Koopman P. Control of mammalian germ cell entry into meiosis. Mol Cell Endocrinol 2014; 382: 488-497.

  11. Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of de esta hormona, con una significancia clínica para las diversas aplicaciones que posee [131,133]. No obstante, el estuche AMH/ MIS ELISA Ultrasensible, ajustado a las condiciones de cada laboratorio y población de estudio, representa una herramienta útil para la cuantificación de los niveles de la hormona antimülleriana, que ha demostrado buen desempeño y validez, y que se encuentra disponible en nuestro medio para la medición de la función ovárica en las mujeres, con aplicabilidad clínica. mammalian gonad development. Nat Rev Endocrinol 2014; 10: 673-683.

  12. Mullen RD, Behringer RR. Molecular genetics of Müllerian duct formation, regression and differentiation. Sex Dev 2014; 8: 281-296.

  13. Hampl R, Snajderova M, Mardesic T. Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve. Physiol Res 2011; 60: 217-223.

  14. La Marca A, Volpe A. Anti-müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf) 2006; 64: 603-610.

  15. di Clemente N, Jamin SP, Lugovskoy A, Carmillo P, Ehrenfels C, Picard JY, et al. Processing of Anti-müllerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Mol Endocrinol 2010; 24: 2193-2206.

  16. Lindhardt Johansen M, Hagen CP, Johannsen TH, Main KM, Picard JY, Jorgensen A, et al. Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol 2013; 2013: 198698.

  17. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab 2011; 25: 221- 238.

  18. Hagen CP, Aksglaede L, Sorensen K, Mouritsen A, Andersson AM, Petersen JH, et al. Individual serum levels of Anti-müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod 2012; 27: 861-866.

  19. Lashen H, Dunger DB, Ness A, Ong KK. Peripubertal changes in circulating antimüllerian hormone levels in girls. Fertil Steril 2013; 99: 2071-2075.

  20. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One 2010; 5: e8772.

  21. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011; 95: 170-175.

  22. Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of Anti-müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol 2015; 13: 137.

  23. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS, Table ESIGfRE--AR. Anti-müllerian hormone (AMH): what do we still need to know? Hum Reprod 2009; 24: 2264-2275.

  24. Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod 2010; 25: 1282-1287.

  25. Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, et al. Which follicles make the most Anti-müllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013; 19: 519-527.

  26. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001; 142: 4891-4899.

  27. Grynberg M, Pierre A, Rey R, Leclerc A, Arouche N, Hesters L, et al. Differential regulation of ovarian Anti-müllerian hormone (AMH) by estradiol through alpha- and beta-estrogen receptors. J Clin Endocrinol Metab 2012; 97: E1649-1657.

  28. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, et al. Control of primordial follicle recruitment by Anti-müllerian hormone in the mouse ovary. Endocrinology 1999; 140: 5789-5796.

  29. Visser JA, Durlinger AL, Peters IJ, van den Heuvel ER, Rose UM, Kramer P, et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in Anti-müllerian hormone null mice. Endocrinology 2007; 148: 2301-2308.

  30. Grossman MP, Nakajima ST, Fallat ME, Siow Y. Müllerian- inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 2008; 89: 1364-1370.

  31. Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Mollgard K, Wreford Andersen E, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011; 17: 63-70.

  32. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, et al. Anti-müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011; 22: 341-349.

  33. Almog B, Shehata F, Suissa S, Holzer H, Shalom-Paz E, La Marca A, et al. Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study. Fertil Steril 2011; 95: 2359-2363, 2363 e2351.

  34. Gougeon A. Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Maturitas 1998; 30: 137-142.

  35. Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, et al. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril 2009; 92: 1674-1678.

  36. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod 2012; 27: 594-608.

  37. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF, 3rd. Association of Anti-müllerian hormone levels with obesity in late reproductive-age women. Fertil Steril 2007; 87: 101-106.

  38. Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Antimüllerian hormone and obesity: insights in oral contraceptive users. Contraception 2010; 81: 245-248.

  39. Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, Witchel SF, et al. Serum Anti-müllerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab 2010; 95: 1786-1792.

  40. Halawaty S, ElKattan E, Azab H, ElGhamry N, Al-Inany H. Effect of obesity on parameters of ovarian reserve in premenopausal women. J Obstet Gynaecol Can 2010; 32: 687-690.

  41. Skalba P, Cygal A, Madej P, Dabkowska-Huc A, Sikora J, Martirosian G, et al. Is the plasma Anti-müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2011; 158: 254-259.

  42. La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG 2012; 119: 1171-1179.

  43. La Marca A, Spada E, Grisendi V, Argento C, Papaleo E, Milani S, et al. Normal serum Anti-müllerian hormone levels in the general female population and the relationship with reproductive history. Eur J Obstet Gynecol Reprod Biol 2012; 163: 180-184.

  44. Overbeek A, Broekmans FJ, Hehenkamp WJ, Wijdeveld ME, van Disseldorp J, van Dulmen-den Broeder E, et al. Intra-cycle fluctuations of Anti-müllerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online 2012; 24: 664-669.

  45. Plante BJ, Cooper GS, Baird DD, Steiner AZ. The impact of smoking on antimüllerian hormone levels in women aged 38 to 50 years. Menopause 2010; 17: 571-576.

  46. Freour T, Masson D, Dessolle L, Allaoua D, Dejoie T, Mirallie S, et al. Ovarian reserve and in vitro fertilization cycles outcome according to women smoking status and stimulation regimen. Arch Gynecol Obstet 2012; 285: 1177-1182.

  47. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 2007; 23: 486-493.

  48. Dafopoulos A, Dafopoulos K, Georgoulias P, Galazios G, Limberis V, Tsikouras P, et al. Smoking and AMH levels in women with normal reproductive history. Arch Gynecol Obstet 2010; 282: 215-219.

  49. Waylen AL, Jones GL, Ledger WL. Effect of cigarette smoking upon reproductive hormones in women of reproductive age: a retrospective analysis. Reprod Biomed Online 2010; 20: 861-865.

  50. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006; 91: 4057-4063.

  51. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum Anti-müllerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21: 3103-3107.

  52. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of Anti-müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 2007; 22: 1837-1840.

  53. Sowers M, McConnell D, Gast K, Zheng H, Nan B, Mc- Carthy JD, et al. Anti-müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94: 1482-1486.

  54. Dolleman M, Verschuren WM, Eijkemans MJ, Dolle ME, Jansen EH, Broekmans FJ, et al. Reproductive and lifestyle determinants of Anti-müllerian hormone in a large population-based study. J Clin Endocrinol Metab 2013; 98: 2106-2115.

  55. Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 2013; 99: 1305-1310.

  56. Nelson SM, Stewart F, Fleming R, Freeman DJ. Longitudinal assessment of antimüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 2010; 93: 1356-1358.

  57. Koninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, et al. Anti-müllerian-hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol 2013; 11: 60.

  58. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, et al. Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992; 326: 466-471.

  59. Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, Zeller WP, et al. Anti-müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 2000; 31: 1202-1208.

  60. Chang HL, Pahlavan N, Halpern EF, MacLaughlin DT. Serum Müllerian Inhibiting Substance/Anti-müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol 2009; 114: 57-60.

  61. Rey RA, Lhomme C, Marcillac I, Lahlou N, Duvillard P, Josso N, et al. Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 1996; 174: 958-965.

  62. Farkkila A, Koskela S, Bryk S, Alfthan H, Butzow R, Leminen A, et al. The clinical utility of serum Anti- müllerian hormone in the follow-up of ovarian adulttype granulosa cell tumors--A comparative study with inhibin B. Int J Cancer 2015; 137: 1661-1671.

  63. Chin TW, Parry RL, Donahoe PK. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 1991; 51: 2101-2106.

  64. Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Füller AF, Jr., Shah PC, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Müllerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999; 5: 3488-3499.

  65. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, et al. Müllerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 2000; 275: 37101-37109.

  66. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370: 685-697.

  67. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti- müllerian hormone: a new marker for ovarian function. Reproduction 2006; 131: 1-9.

  68. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC. Changes in Anti-müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 2004; 19: 2036-2042.

  69. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum Anti-müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20: 1820-1826.

  70. Kaya C, Pabuccu R, Satiroglu H. Serum antimüllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. Fertil Steril 2010; 94: 2202-2207.

  71. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al. Granulosa cell production of Anti-müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007; 92: 240-245.

  72. Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti- müllerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 2122-2126.

  73. Bungum L, Franssohn F, Bungum M, Humaidan P, Giwercman A. The circadian variation in Anti-müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women. PLoS One 2013; 8: e68223.

  74. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-müllerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Dis Markers 2016; 2016: 5246217.

  75. Lebkowska A, Kowalska I. Anti-müllerian hormone and polycystic ovary syndrome. Endokrynol Pol 2017; 68: 74-78.

  76. Eilertsen TB, Vanky E, Carlsen SM. Anti-müllerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012; 27: 2494-2502.

  77. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26: 3123-3129.

  78. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can Anti-müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013; 98: 3332-3340.

  79. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014; 20: 334-352.

  80. Kallio S, Aittomaki K, Piltonen T, Veijola R, Liakka A, Vaskivuo TE, et al. Anti-müllerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Hum Reprod 2012; 27: 854-860.

  81. Chao KC, Ho CH, Shyong WY, Huang CY, Tsai SC, Cheng HY, et al. Anti-müllerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. J Chin Med Assoc 2012; 75: 70-74.

  82. Visser JA, Schipper I, Laven JS, Themmen AP. Anti- müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 2012; 8: 331-341.

  83. Baker VL. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet Gynecol 2013; 25: 375-381.

  84. Leader B, Baker VL. Maximizing the clinical utility of antimüllerian hormone testing in women’s health. Curr Opin Obstet Gynecol 2014; 26: 226-236.

  85. Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, et al. High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil Steril 2012; 98: 1037-1042.

  86. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113-130.

  87. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and Anti-müllerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG 2004; 111: 1248-1253.

  88. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 Anti-müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin- releasing hormone agonist--gonadotropin treatment. Hum Reprod 2005; 20: 915-922.

  89. Broer SL, Mol B, Dolleman M, Fauser BC, Broekmans FJ. The role of Anti-müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 2010; 22: 193-201.

  90. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006; 85: 1541-1543.

  91. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Anti-müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009; 24: 867-875.

  92. Karkanaki A, Vosnakis C, Panidis D. The clinical significance of Anti-müllerian hormone evaluation in gynecological endocrinology. Hormones (Athens) 2011; 10: 95-103.

  93. Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R, et al. Anti-müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 1796- 1802.

  94. Wunder DM, Guibourdenche J, Birkhauser MH, Bersinger NA. Anti-müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/ intracytoplasmic sperm injection. Fertil Steril 2008; 90: 2203-2210.

  95. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002; 77: 357- 362.

  96. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum Anti-müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003; 18: 323-327.

  97. van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004; 11: 601- 606.

  98. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause 2012; 19: 387-395.

  99. Dolleman M, Depmann M, Eijkemans MJ, Heimensem J, Broer SL, van der Stroom EM, et al. Anti-müllerian hormone is a more accurate predictor of individual time to menopause than mother’s age at menopause. Hum Reprod 2014; 29: 584-591.

  100. Ramezani Tehrani F, Dolleman M, van Disseldorp J, Broer SL, Azizi F, Solaymani-Dodaran M, et al. Predicting menopausal age with Anti-müllerian hormone: a cross-validation study of two existing models. Climacteric 2014; 17: 583-590.

  101. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, et al. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008; 23: 674-678.

  102. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007; 12: 141-147.

  103. Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012; 97: 2059-2067.

  104. Lunsford AJ, Whelan K, McCormick K, McLaren JF. Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertil Steril 2014; 101: 227-231.

  105. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013; 99: 477-483.

  106. Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment Anti-müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013; 49: 3404-3411.

  107. Urman B, Alper E, Yakin K, Oktem O, Aksoy S, Alatas C, et al. Removal of unilateral endometriomas is associated with immediate and sustained reduction in ovarian reserve. Reprod Biomed Online 2013; 27: 212-216.

  108. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 3146-3154.

  109. Somigliana E, Berlanda N, Benaglia L, Vigano P, Vercellini P, Fedele L. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications. Fertil Steril 2012; 98: 1531-1538.

  110. Grynnerup AG, Lindhard A, Sorensen S. Anti-müllerian hormone levels in salpingectomized compared with nonsalpingectomized women with tubal factor infertility and women with unexplained infertility. Acta Obstet Gynecol Scand 2013; 92: 1297-1303.

  111. Ni L, Sadiq S, Mao Y, Cui Y, Wang W, Liu J. Influence of various tubal surgeries to serum antimüllerian hormone level and outcome of the subsequent IVF-ET treatment. Gynecol Endocrinol 2013; 29: 345-349.

  112. Sahmay S, Usta T, Erel CT, Imamoglu M, Kucuk M, Atakul N, et al. Is there any correlation between amh and obesity in premenopausal women? Arch Gynecol Obstet 2012; 286: 661-665.

  113. Rachon D, Teede H. Ovarian function and obesity--interrelationship, impact on women’s reproductive lifespan and treatment options. Mol Cell Endocrinol 2010; 316: 172-179.

  114. Metwally M, Ledger WL, Li TC. Reproductive endocrinology and clinical aspects of obesity in women. Ann N Y Acad Sci 2008; 1127: 140-146.

  115. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009; 296: E238-243.

  116. Katsikis I, Karkanaki A, Misichronis G, Delkos D, Kandaraki EA, Panidis D. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 156: 181-185.

  117. Merhi ZO, Minkoff H, Feldman J, Macura J, Rodriguez C, Seifer DB. Relationship of bariatric surgery to Müllerian- inhibiting substance levels. Fertil Steril 2008; 90: 221-224.

  118. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, et al. The effect of weight loss on Anti- müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009; 24: 1976-1981.

  119. Baker ML, Metcalfe SA, Hutson JM. Serum levels of müllerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab 1990; 70: 11-15.

  120. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, et al. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990; 70: 16-22.

  121. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R. An enzyme linked immunoassay for Anti-müllerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab 1990; 70: 23-27.

  122. Carre-Eusebe D, Imbeaud S, Harbison M, New MI, Josso N, Picard JY. Variants of the Anti-müllerian hormone gene in a compound heterozygote with the persistent Müllerian duct syndrome and his family. Hum Genet 1992; 90: 389-394.

  123. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P, Cailla H, et al. Detection of minimal levels of serum Anti-müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000; 85: 540-544.

  124. Al-Qahtani A, Muttukrishna S, Appasamy M, Johns J, Cranfield M, Visser JA, et al. Development of a sensitive enzyme immunoassay for Anti-müllerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrinol (Oxf) 2005; 63: 267-273.

  125. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D. Measurement of serum Anti-müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 2007; 375: 162-164.

  126. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE. Development of a second generation Anti-müllerian hormone (AMH) ELISA. J Immunol Methods 2010; 362: 51-59.

  127. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23: 411-420.

  128. Ansh Labs LLC. Ultra-Sensitive AMH/MIS ELISA. 2014. Disponible: https://www.anshlabs.com/wp-content/ uploads/inserts/AL105.pdf. Consultado: jun 2017.

  129. Groome N. The design features and performance of a state-of-the-art fully-automated Anti-müllerian hormone assay for the Beckman Access Family of immunoassay systems. 2015. Beckman Coulter. Disponible: http://www.beckmancoulter-amh.com/en/ wp-content/uploads/Access-AMH-Technical-Bulletin- 14-07-2015.pdf. Consultado: jun 2017.

  130. Roche Diagnostics International Ltd. Elecsys® AMH. 2014. Disponible: http://www.cobas.com/content/dam/ cobas_com/pdf/product/Elecsys%20AMH/Elecsys%20 AMH%20FactSheet.pdf. Consultado: jun 2017.

  131. Li HW, Wong BP, Ip WK, Yeung WS, Ho PC, Ng EH. Comparative evaluation of three new commercial immunoassays for Anti-müllerian hormone measurement. Hum Reprod 2016; 31: 2796-2802.

  132. Mayo Medical Laboratories. Antimüllerian Hormone (AMH), Serum. 2017. Mayo Foundation for Medical Education and Research. Disponible: https://www. mayomedicallaboratories.com/test-catalog/Overview/ 89711. Consultado: jun 2017.

  133. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new Anti-müllerian hormone assays and comparison with the current clinical standard assay. Hum Reprod 2014; 29: 1035-1041.

  134. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, et al. Anti-müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011; 96: 2532-2539.

  135. Nair S, Slaughter JC, Terry JG, Appiah D, Ebong I, Wang E, et al. Anti-müllerian hormone (AMH) is associated with natural menopause in a population-based sample: The CARDIA Women’s Study. Maturitas 2015; 81: 493-498.

  136. Kruszynska A, Slowinska-Srzednicka J. Anti-müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny 2017; 16: 47-50.

  137. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013; 99: 963-969.

  138. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2012; 98: 1407-1415.

  139. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12: 685-718.

  140. Al-Qahtani A, Groome NP. Editorial: Anti-müllerian hormone: Cinderella finds new admirers. J Clin Endocrinol Metab 2006; 91: 3760-3762.




2020     |     www.medigraphic.com